Subscribe to our newsletter to receive the latest product updates and special offers

Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Revenue Breakdown and Options Chain

Gain deeper insights into company revenues with a detailed analysis of revenue sources.
Explore the updated Options feature, providing in-depth data, and a 3D viewing option.

Last Close
Apr 12 04:00PM ET
Dollar change
Percentage change
CategoryUS Equities - Industry Sector Asset TypeEquities (Stocks) TagsU.S. Return% 1Y27.10% Shs Outstand Perf Week-1.93%
SponsorALPS ETF Type Tagsequity Return% 3Y-10.07% Total Holdings95 Perf Month-7.35%
Fund Family Bond Type Tagshealthcare Return% 5Y-0.98% AUM110.37M Perf Quarter2.97%
IndexS-Network Medical Breakthroughs Index Average Maturity Tagsbiotechnology Return% 10Y NAV% Perf Half Y27.90%
Index Weighting Commodity Type Tagssmall-mid-cap Return% SI NAV/sh Perf Year23.63%
Active/Passive Quant Type Tagsmedical Flows% 1M-0.76% 52W Range23.21 - 38.80 Perf YTD1.14%
Dividend TTM0.07 (0.21%) ESG Type Tagsclinical-trials Flows% 3M4.42% 52W High-14.13% Beta0.90
Dividend Ex-DateDec 21, 2023 Dividend Type Sector/Theme Flows% YTD4.42% 52W Low43.55% ATR (14)0.82
Expense0.50% Structure Type Region Flows% 1Y RSI (14)39.99 Volatility1.76% 2.03%
Option/ShortYes / Yes Growth/Value Dev/Emerg Flows% 3Y Rel Volume0.33 Prev Close34.45
Inverse/Leveraged Market Cap Currency Flows% 5Y Avg Volume12.86K Price33.32
SMA20-4.02% SMA50-5.79% SMA2008.62% Trades Volume4,237 Change-3.28%
Feb-29-24 07:00AM
Jun-30-22 08:51AM
Apr-04-22 07:30AM
Mar-24-22 08:42AM
Mar-22-22 07:00AM
04:58PM Loading…
Aug-20-20 04:58PM
Jun-23-20 11:10AM
Apr-14-20 04:00PM
Feb-21-20 11:42AM
Feb-10-20 01:40PM
Dec-26-19 02:30PM
Dec-24-19 12:15PM
Dec-23-19 12:00PM
Dec-20-19 02:00PM
Dec-12-19 08:00AM
04:16PM Loading…
Dec-10-19 04:16PM
Dec-02-19 02:40PM
Nov-27-19 11:05AM
Nov-21-19 12:15PM
Nov-01-19 11:10AM
Oct-31-19 12:25PM
Oct-30-19 10:43AM
Oct-23-19 04:24PM
Sep-09-19 04:55PM
Sep-03-19 05:46PM
Aug-05-19 12:00PM
Jun-24-19 04:23PM
09:55AM Loading…
Jun-18-19 09:55AM
Jun-17-19 03:22PM
May-15-19 01:00PM
May-06-19 06:05PM
Apr-11-19 03:33PM
Apr-10-19 03:21PM
Mar-06-19 05:05PM
Feb-28-19 01:00PM
Feb-27-19 03:00PM
Feb-26-19 11:15AM
Feb-25-19 01:59PM
Feb-14-19 01:53PM
Jan-23-19 09:16AM
Jan-22-19 10:15AM
Jan-14-19 01:00PM
Jan-07-19 01:56PM
Dec-27-18 02:30PM
Nov-20-18 02:03PM
Oct-23-18 09:18AM
Oct-10-18 03:30PM
Sep-28-18 07:37AM
Sep-06-18 11:00AM
Jul-12-18 03:23PM
Jul-03-18 04:42PM
Jul-02-18 03:23PM
Jun-28-18 12:25PM
May-31-18 04:36PM
May-21-18 02:20PM
May-11-18 04:18PM
Apr-16-18 08:00AM
Mar-27-18 12:42PM
Jan-11-18 10:57AM
Jan-10-18 12:18PM
Dec-28-17 02:27PM
Dec-22-17 04:16PM
Sep-12-17 03:08PM
Aug-29-17 12:44PM
Aug-28-17 02:37PM
Jul-06-17 06:07PM
Jun-19-17 05:18PM
Jun-01-17 01:12PM
May-18-17 10:19AM
May-08-17 05:42PM
Mar-21-17 12:19PM
Mar-01-17 04:14PM
Feb-23-17 11:45AM
Jan-12-17 12:00PM
Dec-08-16 03:00PM
Nov-14-16 01:54PM
Nov-10-16 09:55AM
Nov-01-16 12:46PM
Oct-27-16 12:19PM
Oct-21-16 09:54AM
Sep-21-16 11:23AM
Sep-14-16 02:19PM
Sep-12-16 02:47PM
Aug-19-16 12:14PM
Aug-01-16 08:00AM
Jul-20-16 02:23PM
Jul-05-16 10:53AM
Jun-22-16 10:40AM
Apr-15-16 11:33AM
Apr-07-16 11:30AM
Apr-06-16 11:38AM
Feb-05-16 09:48AM
Feb-03-16 01:05PM
ALPS Medical Breakthroughs ETF seeks investment results that correspond (before fees and expenses) generally to the performance of its underlying index, the S-Network Medical Breakthroughs Index. The fund employs a "passive management" - or indexing - investment approach designed to track the performance of the underlying index. It will normally invest at least 80% of its net assets in securities that comprise the underlying index. The underlying index is comprised of small and mid-cap stocks of biotechnology companies that have one or more drugs in either Phase II or Phase III of the U.S. Food and Drug Administration clinical trials.